Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ: TEM )

59.81 -8.27 (-12.15%)
Streaming Delayed Price Updated: 12:07 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The recent stock market dip provided some discounts. 
Via The Motley Fool
AST SpaceMobile And Rocket Lab Are Among Top 7 Best Performing Mid-Cap Stocks Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?
Seven mid-cap stocks soared last week, including ASTS, TEM, INTA, LOAR, RKLB, QFIN, and LITE. Have you added them to your portfolio? 
Via Benzinga
TEM Stock Earnings: Tempus AI Beats EPS, Beats Revenue for Q2 2024
TEM stock results show that Tempus AI beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment
Tempus AI stock is at all-time high of $47.81, up 17.27% since IPO in June. SoftBank invested $189 million in the company. 
Via Benzinga
Topics Artificial Intelligence Initial Public Offering
Exposures Artificial Intelligence Securities Market
7 Growth Stocks to Buy on Corrections for 3X Returns by 2026
These are the growth stocks to buy on corrections as they represent fundamentally strong companies with impending growth catalysts. 
Via InvestorPlace
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
From Tempus AI, Inc.
Via Business Wire
7 Growth Stocks That Could 7X in the Next 7 Years
Investors consider these growth stocks to buy since they represent companies with good fundamentals and a positive industry outlook. 
Via InvestorPlace
Tempus Reports Second Quarter 2024 Results
From Tempus AI, Inc.
Via Business Wire
Cathie Wood Buys $28 Million Of Amazon, Targets Crypto; Sells $26 Million Of This Stock
Cathie Wood bought the dip on Amazon stock, Coinbase, Robinhood, Meta and more. ARK Invest unloaded on tech names. 
Via Investor's Business Daily
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor kicked off the new trading week by buying when others were selling. 
Via The Motley Fool
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns
These under-the-radar healthcare stocks are on a high growth trajectory and represent companies that recently went public. 
Via InvestorPlace
3 AI-Powered Healthcare Stocks Transforming Medicine
Invest in AI healthcare stocks to benefit significantly from tech that could propel the healthcare market to $148.4 billion by 2029. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 New Growth Stock Listings That Can Be Long-Term Wealth Creators
These are the new growth stocks to buy as they represent under-the-radar companies with sustained growth potential 
Via InvestorPlace
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics
From Tempus AI, Inc.
Via Business Wire
3 AI-in-Healthcare Stocks to Buy for Outsized Returns
These are the AI healthcare stocks to buy as they represent medical technology investing in research and development for accelerated growth. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Growth Stocks That Can Create Millionaires by 2030
These are the millionaire-maker growth stocks to buy as they represent companies with good fundamentals and a big addressable market. 
Via InvestorPlace
Riot Platforms & North Face Parent V.F. Corp Are Among 11 Mid-Cap Stocks That Performed The Best Last Week (July 14-July 20): Are Others In Your Portfolio?
Top mid-cap stock performers: VIRT (+30%), VFC (+22%), NFE (+20%), RIOT (+16%), CLVT (+14%), AMN (+14%), BKU (+13%), MARA (+12%), EXPI (+12%), ZETA (+11%), NATL (+11%). 
Via Benzinga
7 Millionaire-Making Growth Stocks to Buy and Forget
These are the millionaire-maker growth stocks to buy for the long term as they represent quality companies in a big addressable market. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
A couple of the names you might not recognize -- yet. 
Via The Motley Fool
Tempus to Report Second Quarter 2024 Financial Results on August 6
From Tempus AI, Inc.
Via Business Wire
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
From Tempus AI, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
3 Under-the-Radar IPO Stocks to Buy Before They Double
These are the under-the-radar IPO stocks to buy as they represent growth companies with an attractive business outlook. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
IPOs 2024: Tempus AI Addresses Medical Diagnostic Use Case
Tempus has been growing at a strong clip. Its revenues increased from $257.9 million in 2021 to $320.7 million in 2022 and to $531.8 million last year. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Surpasses 500 Research Publications
From Tempus AI, Inc.
Via Business Wire
Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says
William Blair initiated coverage on Tempus AI, highlighting its unique approach and business model in healthcare technology. The company, which leverages AI to analyze molecular, clinical, and genomic... 
Via Benzinga
Topics Artificial Intelligence Initial Public Offering
Exposures Artificial Intelligence Securities Market
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.